BARC has developed a plant lectin based formulation for prophylactic protection against oxidative stress induced toxicity, morbidity and mortality. It is proposed to genetically modify the sequence of this protein and prepare at least ten different variants. A new candidate with better efficacy and minimum side effects will be selected after evaluation of variants.

Deliverables:

1. Generation of variants of the parent molecule.
2. Over-expression and purification of the molecule at laboratory scale for further testing & evaluation.
3. Development of formulation suitable for administration to humans and manufacture of the same under GMP conditions.